EVALUATION OF SERUM EOSINOPHIL-DERIVED NEUROTOXIN IN CHILDREN AS A BIOMARKER FOR ASTHMA DIAGNOSIS AND CONTROL

Asthma symptoms include wheezing, coughing, dyspnea, and chest tightness, as well variable degrees of airway blockage hyper-responsiveness. Many biomarkers have been widely studied in asthmatic children for asthma diagnosis monitoring. Clinical decisions related to control status traditionally based on subjective symptoms, rescue medication use, lung function changes. Biomarkers reflecting remain controversial. Although a standard definition eosinophilic has not developed yet, peripheral blood eosinophil counts ≥150 cells/µL, ≥300 or ≥400 cells/µL used trials adult populations describe can readily be identified primary care setting. Specific used, including count, sputum count (%), fractional excretion nitric oxide (FeNO), serum periostin level. One the emerging is Eosinophil-derived neurotoxin (EDN), which degranulated protein. Bronchoconstriction hyper-responsiveness are more closely associated with presence eosinophil-derived neurotoxic eosinophil-cationic protein (ECP) inflamed airways.